The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001367336
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
24/09/2026
Date registered
Help: Date registered
16/11/2026
Date last updated
Help: Date last updated
16/11/2026
Date data sharing statement initially provided
Help: Data sharing statement date
16/11/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
An observational study comparing the autonomic nervous system and blood markers in people with heart symptoms but no major coronary artery blockages, people with coronary artery blockages, and healthy volunteers
Scientific title
A longitudinal observational study characterising a distinct profile of autonomic function and circulating blood biomarkers in adults with non-obstructive coronary artery disease compared with adults with obstructive atherosclerotic coronary artery disease and healthy controls
Additional trial identifiers [1] 318499 0
Nil
Universal Trial Number (UTN)
Trial acronym
INFO-NOCA (Novel INfluential Factors in the natural histOry of Non-Obstructive Coronary Artery diseases)
Related trial records

Health condition
Health condition(s) studied:
Myocardial Infarction 343689 0
Spontaneous Coronary Artery Dissection 343690 0
Vasospastic Angina 343691 0
Atherosclerotic coronary artery disease 343692 0
Postural Orthostatic Tachycardia Syndrome 343693 0
Systemic inflammatory conditions 343694 0
Autonomic Dysfunction 343702 0
Endothelial Dysfunction 343703 0
Condition category
Condition code
Cardiovascular 339811 339811 0 0
Coronary heart disease
Cardiovascular 339812 339812 0 0
Other cardiovascular diseases
Neurological 339819 339819 0 0
Other neurological disorders

Intervention/exposure
Study type
Observational
Patient registry
True
Target follow-up duration
5
Target follow-up type
Years
Description of the intervention or exposure
Group 1: Participants with acute myocardial infarction caused by coronary atherosclerosis
Group 2: Participants recently diagnosed with spontaneous coronary artery dissection (SCAD)
Group 3: Participants diagnosed with vasospastic angina (VSA)
Group 4: Participants with a prior SCAD diagnosis (more than one year ago)
Group 5: Healthy control participants


The following section provides a brief summary of the study procedures that participants will undergo during each visit.

Baseline / Enrolment (In-person)
Applicable to all participants
• Study overview provided and written informed consent obtained
• Collection of clinical and imaging data (e.g., Invasive angiographic data, Computed tomography coronary angiography (CTCA) and CT angiography head to pelvis, Echocardiograms, Cardiac Magnetic Resonance Imaging (MRI))
• Collection of 50 mL fasting blood sample for exploratory analysis

Only Group 3, 4, and 5 participants will undergo:
• Measurement of vital signs (blood pressure, temperature, heart rate, height and weight) and pupillary light reflex
• Full autonomic and vascular/endothelial function testing (see detailed protocol below)
• Completion of self-reported questionnaires
• Collection of routine blood testing results
• 24-hour Holter monitoring and ambulatory BP measurement

Visit 2: 3 months ± 4 weeks (In-person)
Applicable to Group 1 and 2 participants only
• Review of current medications and recovery status
• Measurement of vital signs and pupillary light reflex
• Completion of self-report questionnaires
• Full autonomic and endothelial function testing
• Collection of routine blood testing results
• Collection of 50 mL fasting blood sample for exploratory analysis
• 24-hour Holter monitoring and ambulatory BP measurement
Visit 3: 12 months ± 4 weeks (In-person)
Applicable to Group 1, 2 and 3 participants only
• Review of medical history and current medications
• Collection of any new clinical data since the previous visit
• Measurement of vital signs and pupillary light reflex.
• Completion of self-report questionnaires
• Collection of routine blood testing results
• Collection of 50 mL fasting blood sample for exploratory analysis
• Shortened autonomic function testing protocol
• 24-hour Holter monitoring and ambulatory BP measurement
Visit 4: Three years post-enrolment
Applicable to Group 1, 2, 3 and 4 participants
• Review of clinical events post-last contact
• Review of medications
• Groups 1 and 2 only: Completion of a short survey for symptom burden and QoL assessment

Visit 5: Five years post-enrolment
Applicable to Group 1, 2, 3 and 4 participants
• Review of clinical events post-last contact
• Review of medications
• Groups 1 and 2 only: Completion of a short survey for symptom burden and QoL assessment
Intervention code [1] 335412 0
Not applicable
Description of the comparator or control
• Group 5: Healthy Control (Baseline visit only)
Healthy volunteers with no history of cardiovascular, renal, respiratory, neurological, or systemic inflammatory conditions. Control participants will be recruited via university networks, community advertisements, and outpatient flyers.

Control group
Active

Outcomes
Primary outcome [1] 346987 0
(This is the composite primary outcome) The proportion of participants with moderate to severe autonomic dysfunction, measured by Composite Autonomic Scoring Scale (CASS) score of 4 to 10, in patients with NOCA compared with obstructive coronary artery disease and healthy controls at baseline.
Timepoint [1] 346987 0
Baseline
Secondary outcome [1] 468491 0
(Note: This should be a composite outcome, as Group 1,2, and 3will be compared between each other over the 12-month follow-up and evaluated its changes with the association in persisted symptoms.) Changes in quality of life over a 12-month follow-up in Groups 1, 2 and 3 associated with persistence of symptoms
Timepoint [1] 468491 0
12-month follow-up Note: This full set of questionnaires is administered only at baseline and at the 12-month follow-up.)
Secondary outcome [2] 468950 0
Changes in autonomic-endothelial interlinked function over a 12-month follow-up in Groups 1, 2 and 3.
Timepoint [2] 468950 0
Baseline and 12 months
Secondary outcome [3] 469852 0
Occurrence of a composite cardiovascular outcome comprising myocardial infarction, recurrent spontaneous coronary artery dissection (SCAD), unplanned coronary revascularisation, and cardiovascular-related hospitalisation, assessed through participant follow-up and review of available medical records.
Timepoint [3] 469852 0
3- and 5-year follow-up

Eligibility
Key inclusion criteria
• Adults aged 18 to 65 years; and
• Patients who have experienced acute myocardial infarction due to coronary atherosclerosis (Group 1); OR
• Patients who have undergone clinically indicated invasive coronary angiography for acute myocardial infarction due to spontaneous coronary artery dissection (Group 2), OR
• Patients with angina confirmed to be due to vasospastic angina (Group 3), OR
• Patients with a confirmed diagnosis of spontaneous coronary artery dissection more than one year prior (Group 4); OR
• Healthy individuals without history of cardiovascular, renal, respiratory, liver, neurological, or systemic inflammatory conditions (Group 5). OR
* Patients with a confirmed diagnosis of Postural Orthostatic Tachycardia Syndrome (Group 6);

Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
• Inability to provide informed consent
• Inability to safely withhold rate-limiting/prescribed medications for autonomic testing
• Terminal illness, precluding completion of 12 months of follow-up
• Cognitive or physical impairments limiting cooperation, or inability to complete autonomic function testing
• Recent major surgery
• Inability or unwillingness to attend follow-up visits at 3- and 12- months (Groups 1 and 2) or at 12- months (Group 3) for Multiple-Visit Groups participants to conduct autonomic function testing and blood collection
• History of haemorrhagic stroke
• Poorly controlled hypertension (blood pressure greater than or equal to 160 mmHg systolic and/or greater than or equal to 95 mmHg diastolic)
• Left ventricular ejection fraction <40%

Study design
Purpose
Natural history
Duration
Longitudinal
Selection
Defined population
Timing
Both
Statistical methods / analysis
The data collected will be de-identified and analysed using a range of descriptive, comparative, and multivariable methods to address the study’s aims and test the central hypothesis. Initial analyses will involve descriptive statistics to summarise demographic, clinical characteristics, autonomic nervous system (ANS) and vascular function, and patient-reported outcomes across the defined participant groups. Continuous variables (e.g., heart rate varibility - HRV, % flow-mediated dilation) will be presented as mean ± standard deviation or median with interquartile ranges depending on data distribution, while categorical variables (e.g., sex, comorbidity presence) will be summarised as frequencies and percentages.
Comparisons between study-specific groups will be conducted to assess differences in autonomic function, endothelial and vascular health, inflammatory biomarkers, symptom burden, and quality of life (QoL). One-way ANOVA or Kruskal-Wallis tests will be applied depending on data type with multiple comparison corrections where appropriate. Categorical variables will be compared using Chi-square or Fisher’s exact tests.

To assess longitudinal changes over time within subjects, repeated measures analyses will be performed using linear mixed-effects models for continuous outcomes and generalised estimating equations for categorical data.

Correlational analyses will explore whether associations between autonomic dysfunction, inflammation, and endothelial impairment are interrelated and contribute to symptoms and prognosis in NOCA disease. Pearson or Spearman correlation will be used as appropriate, supplemented by multivariable linear or logistic regression to assess independent relationships between predictors (e.g., CASS score, HRV) and outcomes such as QoL, anxiety, depression, and symptom persistence. In addition, stratified analyses will be conducted to determine whether the relationship between ANS dysfunction and outcomes differs by sex.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 30269 0
The Royal Adelaide Hospital - Adelaide
Recruitment hospital [2] 30270 0
The Queen Elizabeth Hospital - Woodville
Recruitment postcode(s) [1] 46671 0
5000 - Adelaide
Recruitment postcode(s) [2] 46672 0
5011 - Woodville

Funding & Sponsors
Funding source category [1] 323076 0
University
Name [1] 323076 0
Adelaide University Research Cost Centre
Country [1] 323076 0
Australia
Funding source category [2] 323098 0
University
Name [2] 323098 0
Adelaide University Clinical Trial Facility
Country [2] 323098 0
Australia
Primary sponsor type
Other Collaborative groups
Name
South Australian Health and Medical Research Institute
Address
Country
Australia
Secondary sponsor category [1] 326049 0
University
Name [1] 326049 0
Adelaide University
Address [1] 326049 0
Country [1] 326049 0
Australia
Other collaborator category [1] 284131 0
Individual
Name [1] 284131 0
In-kind support from CI Professor Peter Psaltis - Vascular Research Centre
Address [1] 284131 0
Country [1] 284131 0
Australia
Other collaborator category [2] 284132 0
Individual
Name [2] 284132 0
In-kind support from Dr Jessica Marathe - Royal Adelaide Hospital - Cardiology
Address [2] 284132 0
Country [2] 284132 0
Australia
Other collaborator category [3] 284133 0
Individual
Name [3] 284133 0
In-kind support from Dr Marie-Claire Seeley - Adelaide University
Address [3] 284133 0
Country [3] 284133 0
Australia
Other collaborator category [4] 284134 0
Individual
Name [4] 284134 0
In-kind support from Ms Dang Xuan Anh Tran - Adelaide University
Address [4] 284134 0
Country [4] 284134 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 321477 0
Central Adelaide Local Health Network HREC
Ethics committee address [1] 321477 0
Ethics committee country [1] 321477 0
Australia
Date submitted for ethics approval [1] 321477 0
04/12/2025
Approval date [1] 321477 0
16/06/2026
Ethics approval number [1] 321477 0
223334

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 153842 0
Prof Peter Psaltis
Address 153842 0
Vascular Research Centre, Level 6 South, SAHMRI, 870 North Terrace, Adelaide SA 5000
Country 153842 0
Australia
Phone 153842 0
+61 432 359 686
Fax 153842 0
Email 153842 0
Contact person for public queries
Name 153843 0
Dang Xuan Anh Tran
Address 153843 0
Vascular Research Centre, Level 6 South, SAHMRI, 870 North Terrace, Adelaide SA 5000
Country 153843 0
Australia
Phone 153843 0
+61 8 8128 4213
Fax 153843 0
Email 153843 0
Contact person for scientific queries
Name 153844 0
Dang Xuan Anh Tran
Address 153844 0
Vascular Research Centre, Level 6 South, SAHMRI, 870 North Terrace, Adelaide SA 5000
Country 153844 0
Australia
Phone 153844 0
+61 8 8128 4213
Fax 153844 0
Email 153844 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires approval by an ethics committee
What individual participant data might be shared?
• De-identified individual participant data:
• Published results
What types of analyses could be done with individual participant data?
• Systematic reviews and meta-analyses
• Studies exploring new research questions
• Health economic analyses
• Studies testing whether findings can be repeated or confirmed
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
Not yet decided
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: On request to the Principal Investigator (Prof Peter Psaltis, [email protected] OR [email protected]), released as de-identified data under an institutional data-sharing/transfer agreement and subject to ethics approval

Are there extra considerations when requesting access to individual participant data?
Yes: Require institutional data-sharing/transfer agreement and subject to ethics approval



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.